Haleon (HLN) Other Non-Current Liabilities (2021 - 2025)
Haleon (HLN) posted Other Non-Current Liabilities of $39.9 million for Q4 2025, up 11.04% on a QoQ basis from $35.9 million in Q4 2024, and up 11.04% year-over-year from $35.9 million in Q4 2024.
Haleon (HLN) Other Non-Current Liabilities (2021 - 2025) Analysis & Trends
Haleon's Other Non-Current Liabilities history runs 5 years deep, the most recent figure standing at $39.9 million for Q4 2025.
- Quarterly Other Non-Current Liabilities rose 11.04% year-over-year to $39.9 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $39.9 million (up 11.04% YoY) and the FY2025 annual result came in at $39.6 million, up 10.52% from the prior year.
- Other Non-Current Liabilities was $39.9 million for Q4 2025 at Haleon, up from $35.9 million in the prior quarter.
- Across five years, Other Non-Current Liabilities topped out at $48.4 million in Q4 2023 and bottomed at -$34.1 million in Q2 2024.
- A 5-year average of $11.5 million and a median of $18.3 million in 2022 frame the typical range for Other Non-Current Liabilities.
- Annual changes were most pronounced in 2022 — Other Non-Current Liabilities soared 139.28% — and 2023, when it tumbled 264.35%.
- Haleon's Other Non-Current Liabilities stood at $10.8 million in 2021, then surged by 139.28% to $25.8 million in 2022, then surged by 87.58% to $48.4 million in 2023, then dropped by 25.76% to $35.9 million in 2024, then rose by 11.04% to $39.9 million in 2025.
- Business Quant data shows HLN's Other Non-Current Liabilities at $39.9 million in Q4 2025, $35.9 million in Q4 2024, and -$34.1 million in Q2 2024.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn |
| 10 | Vireo Growth | 10.57 Bn | 10.41 Bn | 59.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 39.90 Mn |
| Dec 31, 2024 | 35.94 Mn |
| Jun 30, 2024 | -34.08 Mn |
| Dec 31, 2023 | 48.40 Mn |
| Jun 30, 2023 | -27.53 Mn |
| Dec 31, 2022 | 25.80 Mn |
| Jun 30, 2022 | -7.56 Mn |
| Dec 31, 2021 | 10.78 Mn |